comparemela.com

Latest Breaking News On - Herceptin kadcyla - Page 1 : comparemela.com

Starpharma signs new DEP® agreement with MSD

/PRNewswire/ Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp.

Starpharma signs new DEP agreement with MSD | PressReleasePoint

Melbourne, Australia; 10 August 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has signed a new DEP ® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP ® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021.

Starpharma signs DEP® ADC Research Agreement with MSD

Starpharma signs DEP® ADC Research Agreement with MSD News provided by Share this article Starpharma (ASX: SPL,OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma s proprietary DEP ® technology. Dr Jackie Fairley, CEO of Starpharma commented: MSD is a recognised leader in oncology, and we are delighted to have signed this new Research Agreement in such an innovative and valuable area. DEP ® ADCs exploit the unique potential of Starpharma s DEP

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.